Accredited Chronic Lymphocytic Leukaemia CME Module Launches on EPGonline.org

Tunbridge Wells, United Kingdom, February 11, 2016 --(PR.com)-- A new online CME module is now available in the Chronic Lymphocytic Leukaemia (CLL) Knowledge Centre on epgonline.org. This activity is intended for haematology/oncology specialists and other healthcare professionals involved in the treatment of patients with CLL.

CLL is the most common form of adult leukaemia in the Western world1,2 and the second most common haematological malignancy3. In the UK, CLL accounts for 1% of all new cancer cases and 38% of all cases of leukaemia4. European incidence rates of CLL have increased by around 85% since the 1970s but have started to stabilise in recent years.4 CLL impacts the physical, psychological, social and functional wellbeing of patients5 with fatigue being one of the most frequently reported symptoms.

‘Treatment Optimisation in Chronic Lymphocytic Leukaemia’ has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) and awarded one European CME credit (ECMEC) for successful completion. The module can be accessed at the following address: http://www.epgonline.org/cll-knowledge-centre/cme/treatment-optimisation-in-cll/. Participants must view the five case studies and answer the accompanying quiz questions with a score of 70% or higher in order to pass. Users must be a registered user of epgonline.org in order to access the educational materials. Registration is free and there is no cost to complete this activity.

Director of Content Strategy for epgonline.org, Dr Toby Galbraith, said: “This CME activity has been developed with a strict set of educational objectives in mind. The cases include patients with relapsed CLL, high-risk CLL, or comorbidities, to ensure that the appropriate course of treatment is given in different situations”. This activity is supported by an unrestricted medical education grant from Janssen with no influence on content.

Notes to Editors:

· EPG Health Media (Europe) Ltd publishes www.epgonline.org, an independent website dedicated to providing healthcare professionals worldwide with free access to a comprehensive range of disease and medicines information. Categorised by medical specialty, content within epgonline.org includes a multi-language database of approved medications, treatment guidelines, clinical trial reports, journal abstracts, latest medical industry news, apps and a blog written by members.

· Headquartered in Titusville, New Jersey, Janssen Pharmaceuticals, Inc. is a pharmaceutical company of Johnson & Johnson, providing medicines for an array of health concerns in several therapeutic areas, including: ADHD, general medicine, mental health, neurologics, pain management, and women’s health.

References:

1. Gibson J, Iland HJ Larsen, Brown CM, Joshua DE. Leukaemias into the 21st century – part 2: the chronic leukaemias. Intern Med J. 2013;43:484–94.
2. Hallek M. Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. Am J Hematol. 2013;88:804–16.
3. Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105:1684–92.
4. CRUK (Cancer Research UK) 2014: Chronic lymphocytic leukaemia (CLL) incidence statistics. Updated June 2014 [Accessed 25th March 2015]. Available from: http://www.cancerresearchuk.org
5. Pashos CL, Flowers CR, Kay NE, Weiss M, Lamanna N, Farber C. Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia. Support Care Cancer. 2013;21:2853–60.